FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage
November 14, 2019 - Today, the U.S. Food and Drug Administration granted accelerated approval to zanubrutinib capsules for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma usually responds ...Leggi tutto